Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy

Overview

Journal Theranostics

Date 2016 Nov 24

PMID 27877238

Citations 31

Authors

Kevin A Carter

Dandan Luo

Aida Razi

Jumin Geng

Shuai Shao

Joaquin Ortega

Jonathan F Lovell

Affiliations

Soon will be listed here.

Abstract

Porphyrin-phospholipid (PoP) liposomes can entrap anti-cancer agents and release them in response to near infrared (NIR) light. Doxorubicin, when remotely loaded via an ammonium sulfate gradient at a high drug-to-lipid ratio, formed elongated crystals that altered liposome morphology and could not be loaded into liposomes with higher PoP content. On the other hand, irinotecan could also be remotely loaded but did not form large crystals and did not induce liposome elongation. The loading, stability, and NIR light-triggered release of irinotecan in PoP liposomes was altered by the types of lipids used and the presence of PEGylation. Sphingomyelin, which has been explored previously for liposomal irinotecan, was found to produce liposomes with relatively improved serum stability and rapid NIR light-triggered drug release. PoP liposomes composed from sphingomyelin, cholesterol and 2 molar percent PoP rapidly released irinotecan in vivo in response to NIR irradiation as monitored by intravital microscopy and also induced effective tumor eradication in mice bearing MIA Paca-2 subcutaneous tumor xenografts.

Citing Articles

Fluence Rate-Dependent Kinetics of Light-Triggered Liposomal Doxorubicin Assessed by Quantitative Fluorescence-Based Endoscopic Probe.

Rohrbach D, Carter K, Luo D, Shao S, Aygun-Sunar S, Lovell J Int J Mol Sci. 2025; 26(3).

PMID: 39940981 PMC: 11818813. DOI: 10.3390/ijms26031212.

Engineering photodynamics for treatment, priming and imaging.

Obaid G, Celli J, Broekgaarden M, Bulin A, Uusimaa P, Pogue B Nat Rev Bioeng. 2025; 2(9):752-769.

PMID: 39927170 PMC: 11801064. DOI: 10.1038/s44222-024-00196-z.

Fluence rate-dependent kinetics of light-triggered liposomal doxorubicin assessed by quantitative fluorescence-based endoscopic probe.

Rohrbach D, Carter K, Luo D, Shao S, Aygun-Sunar S, Lovell J Res Sq. 2025; .

PMID: 39801514 PMC: 11722554. DOI: 10.21203/rs.3.rs-5727534/v1.

Fluence rate-dependent kinetics of light-triggered liposomal doxorubicin assessed by quantitative fluorescence-based endoscopic probe.

Rohrbach D, Carter K, Luo D, Shao S, Aygun-Sunar S, Lovell J bioRxiv. 2025; .

PMID: 39763811 PMC: 11703176. DOI: 10.1101/2024.12.29.630668.

Photodynamic Therapy in the Treatment of Cancer-The Selection of Synthetic Photosensitizers.

Aebisher D, Serafin I, Batog-Szczech K, Dynarowicz K, Chodurek E, Kawczyk-Krupka A Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065781 PMC: 11279632. DOI: 10.3390/ph17070932.

References

Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden T . Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000; 60(13):3389-93. View

Mathijssen R, van Alphen R, Verweij J, Loos W, Nooter K, Stoter G . Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001; 7(8):2182-94. View

Modrak D, Rodriguez M, Goldenberg D, Lew W, Blumenthal R . Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int J Oncol. 2002; 20(2):379-84. View

Lasic D, Frederik P, Stuart M, Barenholz Y, McIntosh T . Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 1992; 312(2-3):255-8. DOI: 10.1016/0014-5793(92)80947-f. View

Snyder J, Greco W, Bellnier D, Vaughan L, Henderson B . Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 2003; 63(23):8126-31. View

Allen T, Cullis P . Drug delivery systems: entering the mainstream. Science. 2004; 303(5665):1818-22. DOI: 10.1126/science.1095833. View

Messerer C, Ramsay E, Waterhouse D, Ng R, Simms E, Harasym N . Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 2004; 10(19):6638-49. DOI: 10.1158/1078-0432.CCR-04-0221. View

Torchilin V . Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2):145-60. DOI: 10.1038/nrd1632. View

Chou T, Chen S, Chu I . Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J Biosci Bioeng. 2005; 95(4):405-8. View

10.

Drummond D, Noble C, Guo Z, Hong K, Park J, Kirpotin D . Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006; 66(6):3271-7. DOI: 10.1158/0008-5472.CAN-05-4007. View

11.

Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Suss R . Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006; 1758(10):1633-40. DOI: 10.1016/j.bbamem.2006.05.028. View

12.

Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K . Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 2006; 23(12):2799-808. DOI: 10.1007/s11095-006-9111-5. View

13.

Koo O, Rubinstein I, Onyuksel H . Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2007; 1(3):193-212. DOI: 10.1016/j.nano.2005.06.004. View

14.

Krauze M, Noble C, Kawaguchi T, Drummond D, Kirpotin D, Yamashita Y . Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007; 9(4):393-403. PMC: 1994096. DOI: 10.1215/15228517-2007-019. View

15.

Ganta S, Devalapally H, Shahiwala A, Amiji M . A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008; 126(3):187-204. DOI: 10.1016/j.jconrel.2007.12.017. View

16.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

17.

Hattori Y, Shi L, Ding W, Koga K, Kawano K, Hakoshima M . Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release. 2009; 136(1):30-7. DOI: 10.1016/j.jconrel.2009.01.013. View

18.

You J, Zhang G, Li C . Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano. 2010; 4(2):1033-41. PMC: 2835401. DOI: 10.1021/nn901181c. View

19.

Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2010; 63(3):131-5. DOI: 10.1016/j.addr.2010.03.011. View

20.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View